Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Antonarakis E, Procopio G, Fukasawa S, Tabata K, Park S, Feyerabend S, Drake C, Wu H, Qiu P, Kim J, Poehlein C, Omlin A, Li C, Piulats J, Gross-Goupil M, Goh J, Ojamaa K, Hoimes C, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, de Bono J. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol 2019:JCO1901638.
27.11.2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
27.11.2019
J Clin Oncol 2019:JCO1901638
Antonarakis Emmanuel S, Procopio Giuseppe, Fukasawa Satoshi, Tabata Ken-Ichi, Park Se Hoon, Feyerabend Susan, Drake Charles G, Wu Haiyan, Qiu Ping, Kim Jeri, Poehlein Christian, Omlin Aurelius, Li Chunde, Piulats Josep M, Gross-Goupil Marine, Goh Jeffrey, Ojamaa Kristiina, Hoimes Christopher J, Vaishampayan Ulka, Berger Ranaan, Sezer Ahmet, Alanko Tuomo, de Wit Ronald, de Bono Johann Sebastian
Weiter
